Wednesday, March 30, 2022 Daily Archives

Realizing the Potential of Immune Cell Therapies

by

Remarkable progress is being made in the treatment of cancer. Among the most promising approaches is immune cell therapy, the most prominent type of which is CAR-T therapy. CAR-T therapies have been approved since 2017 and hundreds of clinical trials are now underway. While the race to develop these complex therapies continues to pick up speed, strategies to reduce the steep costs associated with their manufacturing are evolving at a rapid pace. In this article, we outline the factors contributing…

March 30, 2022

Exothera further expands its viral vector capacity

by

The CDMO has expanded its facilities by a further 22,600 square feet to relieve its capacity constraints. Contract development and manufacturing organization (CDMO) Exothera was founded in March 2020 by Belgium-based bioprocess tech firm Univercells, to offer cell and gene therapy developers process development and viral vector manufacturing. After expanding its two facilities in Jumet, Belgium about 25 km south of Brussels, and selecting bioprocess vendor Pall Corporation to equip the roughly 92,000 square feet of space in July 2021,…

March 30, 2022

eTheRNA launches LNP Service

by

eTheRNA Manufacturing introduces a lipid nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical advancement of RNA-based therapeutics and vaccines. According to the RNA technology firm, the LNP service uses eTheRNA’s lipid libraries and formulations to enable targeted delivery and tailored biodistribution solutions. Additionally, the service has been developed to allow customers to maximize the delivery of their RNA-products. “This service can cover product needs for early research and development and can be further optimized…

March 30, 2022